Biocon Limited (NSE:BIOCON)
India
· Delayed Price · Currency is INR 338.20
+8.35 (2.53%)
May 14, 2025, 3:30 PM IST
Biocon Revenue
In the fiscal year ending March 31, 2025, Biocon had annual revenue of 164.70B INR with 11.62% growth. Biocon had revenue of 44.54B in the quarter ending March 31, 2025, with 13.70% growth.
Revenue
164.70B
Revenue Growth
+11.62%
P/S Ratio
2.46
Revenue / Employee
10.09M
Employees
16,315
Market Cap
404.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 164.70B | 17.14B | 11.62% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Biocon News
- 1 day ago - JP Morgan, Goldman Sachs & more: Top stocks on brokers' radar for today - The Times of India
- 2 days ago - Biocon share price falls today – Should you buy, hold or sell? Check what brokerages say - Business Upturn
- 5 days ago - Stocks to watch on May 9: Titan, BPCL, L&T, Biocon, MCX among key movers in trade today - Business Upturn
- 6 days ago - Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore - Business Upturn
- 6 days ago - Stocks in focus: Asian Paints, Titan, LT, Britannia, Biocon among key firms to announce Q4 results today - Business Upturn
- 9 days ago - Biocon share price jumps 4% after its subsidiary receives multiple market access agreements for Yesintek - Business Upturn
- 9 days ago - Biocon Biologics secures US market access for Yesintek - Business Upturn
- 16 days ago - Biocon shares jump over 2% after EU panel’s positive nod for denosumab biosimilars - Business Upturn